We speculate that repurposing and further optimization of such “migraine drugs” (e.g., newly developed antibodies directed against CALCB or RAMP1)38 could perhaps offer novel therapeutic options for EwS patients in the future. The gene discussed is RAMP1; the disease is migraine disorder.